29 completed, 6 terminated, 5 recruiting, 5 unknown. 50 Phase 2, 12 Phase 3, 2 Phase 1.
Follow Polycystic Kidney Diseases: new trials by email Literature Review of Polycystic Kidney Diseases trials Research Report on Polycystic Kidney Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bempedoic Acid Therapy for Polycystic Kidney Disease Bempedoic Acid 180 MG Oral Tablet, Placebo Capsule(s) - ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 2 | Recruiting | Kenneth Hallows | 120 | 2026-09-01 | 2026-09-29 |
| Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) VX-407 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Active not recruiting | Vertex Pharmaceuticals Incorporated | 26 | 2025-11-19 | 2026-09-21 |
| ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) ABBV-CLS-628, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Recruiting | Calico Life Sciences LLC | 240 | 2025-06-09 | 2026-10-06 |
| Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD) JMKX003142 will be administered orally, Plcacebo - ADPKD (Autosomal Dominant Polycystic Kidney Disease) | Phase 2 | Recruiting | Jemincare | 135 | 2025-03-13 | 2025-07-03 |
| Glucagon-Like Peptide-1 Receptor Agonist in ADPKD Tirzepatide, Placebo - Autosomal Dominant Polycystic Kidney, Obesity | Phase 2 | Recruiting | University of Colorado, Denver | 126 | 2025-03-06 | 2025-05-06 |
| Short-term Effects of an SGLT2 Inhibitor on Divalent Ions in Autosomal Dominant Polycystic Kidney Disease Empagliflozin, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Cantonal Hospital Graubuenden | 16 | 2024-09-01 | 2026-09-22 |
| Study of Tamibarotene in Patients With ADPKD Tamibarotene, Placebo - Autosomal Dominant Polycystic Kidney Disease (ADPKD) | Phase 2 | Active not recruiting | Rege Nephro Co., Ltd. | 70 | 2023-12-22 | 2025-04-04 |
| Treat Autosomal Dominant Polycystic Kidney Disease With Oral Ketone Ester? Ketone ester - ADPKD | Phase 2 | Unknown | Universitair Ziekenhuis Brussel | 20 | 2023-11-01 | 2023-10-25 |
| Atorvastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease Atorvastatin 20 Mg Oral Tablet, Sodium Bicarbonate 600 Mg Oral Tablet - Autosomal Dominant Polycystic Kidney Disease, Chronic Kidney Diseases | Phase 2 | Enrolling by invitation | Taipei Medical University Shuang Ho Hospital | 30 | 2023-05-01 | 2023-05-23 |
| Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease Empagliflozin, Placebo - Polycystic Kidney, Autosomal Dominant | Phase 2 | Active not recruiting | University of Colorado, Denver | 50 | 2022-11-18 | 2026-05-01 |
| Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration PB - Autosomal Dominant Polycystic Kidney Disease, Nephrogenic Diabetes Insipidus | Phase 2 | Completed | Mayo Clinic | 36 | 2022-09-01 | 2026-01-27 |
| A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD CAM2029, Placebo - Polycystic Liver Disease | Phase 2 / Phase 3 | Active not recruiting | Camurus AB | 71 | 2022-06-28 | 2026-06-01 |
| A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Leuprorelin - Polycystic Liver Disease, Autosomal Dominant Polycystic Kidney | Phase 2 | Recruiting | University Medical Center Groningen | 36 | 2022-06-01 | 2022-11-04 |
| A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD) GLPG2737, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 66 | 2020-11-10 | 2024-08-22 |
| Pravastatin and Alkali Therapy in Patients With Autosomal Dominant Polycystic Kidney Disease Pravastatin, sodium citrate - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | University of Southern California | 1 | 2019-01-30 | 2025-08-06 |
| Tolvaptan-Octreotide LAR Combination in ADPKD Tolvaptan, Octreotide LAR, Placebo - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Mario Negri Institute for Pharmacological Research | 20 | 2018-12-12 | 2022-11-03 |
| A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients Venglustat, Placebo - Polycystic Kidney, Autosomal Dominant | Phase 2 / Phase 3 | Terminated | Genzyme, a Sanofi Company | 478 | 2018-10-04 | 2023-02-03 |
| The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease Lixivaptan - Autosomal Dominant Polycystic Kidney Disease | Phase 2 | Completed | Palladio Biosciences | 31 | 2018-09-14 | 2022-12-05 |
| A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Bardoxolone methyl capsules - IgA Nephropathy, CKD Associated With Type 1 Diabetes | Phase 2 | Completed | Biogen | 103 | 2017-12-26 | 2025-06-03 |
| Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Tesevatinib, Placebo - Autosomal Dominant Polycystic Kidney, ADPKD | Phase 2 | Completed | Kadmon, a Sanofi Company | 80 | 2017-10-12 | 2023-02-06 |
Showing 20 of 50. Sign in to see all of them.
Polycystic Kidney, Autosomal Dominant (44) · Polycystic liver disease (7) · Kidney Diseases (4) · Hepatomegaly (3) · Liver Diseases (3) · Diabetes Insipidus (2) · Hypertension (2) · Abdominal Pain (1) · Diabetes Insipidus, Nephrogenic (1) · Glomerulonephritis, IGA (1) · Glomerulosclerosis, Focal Segmental (1) · Multiple Pterygium Syndrome, Autosomal Dominant (1) · Obesity (1) · Renal Insufficiency (1)
Abnormalities, Multiple (50) · Ciliopathies (50) · Congenital Abnormalities (50) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (50) · Female Urogenital Diseases (50) · Female Urogenital Diseases and Pregnancy Complications (50) · Genetic Diseases, Inborn (50) · Kidney Diseases, Cystic (50) · Male Urogenital Diseases (50) · Urogenital Diseases (50) · Urologic Diseases (50) · Kidney Diseases (46) · Pathological Conditions, Signs and Symptoms (5) · Digestive System Diseases (3)
Tolvaptan (7) · Sirolimus (5) · XL647 (3) · Metformin (2) · Niacinamide (2) · Tablets (2) · empagliflozin (2) · lanreotide (2) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (1) · Antihypertensive Agents (1) · Atorvastatin (1) · Diet (1) · Everolimus (1) · Leuprolide (1) · MTOR Inhibitors (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (4) · Mario Negri Institute for Pharmacological Research (3) · Mayo Clinic (3) · Radboud University Medical Center (3) · University of Colorado, Denver (3) · Federico II University (2) · Kadmon, a Sanofi Company (2) · A. Manzoni Hospital (1) · Alan Yu, MB, BChir (1) · Biogen (1) · Calico Life Sciences LLC (1) · Camurus AB (1) · Cantonal Hospital Graubuenden (1) · Genzyme, a Sanofi Company (1) · Indiana University (1)
United States (28) · Netherlands (10) · Italy (8) · Belgium (7) · Spain (6) · Germany (5) · Japan (5) · Canada (4) · South Korea (4) · Australia (3) · China (3) · Czechia (3) · France (3) · Poland (3) · United Kingdom (3)
Frank Czerwiec, M.D., Ph.D. (2) · Frederik Nevens, MD, PhD (2) · Loes van Keimpema, MSc (2) · Alan S Yu, MB, BChir (1) · Alan Yu, M.B., B.Chir (1) · Changlin Mei, MD (1) · Curie Ahn, MD, PhD (1) · Dana Miskulin, MD (1) · Erling B Pedersen (1) · Fouad Chebib, MD (1) · Francesco Locatelli, MD (1) · Frank Czerweic, MD (1) · Frank Czerwiec, MD, PhD (1)
PMID 39356039, PMID 41385299, PMID 21903984, PMID 37250503, PMID 38837240, PMID 41348481, PMID 22773240, PMID 26166166, PMID 26844873, PMID 26912555, PMID 27212247, PMID 28810844, PMID 28838955, PMID 32843370, PMID 33768205, PMID 34391872, PMID 36204243, PMID 36535535, PMID 36754009, PMID 37349694, PMID 37986188, PMID 38010035, PMID 40377984
2017 (2), 2014 (1), 2019 (1), R01DK131755 (1), R01DK138915 (1), R21DK104086 (1), R21DK107969 (1), UL1RR024150 (1)